Previous close | 211.54 |
Open | 208.46 |
Bid | 199.28 x 1200 |
Ask | 199.72 x 800 |
Day's range | 199.15 - 213.41 |
52-week range | 177.63 - 262.97 |
Volume | |
Avg. volume | 295,921 |
Market cap | 9.4B |
Beta (5Y monthly) | 1.12 |
PE ratio (TTM) | 26.43 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.36 (0.64%) |
Ex-dividend date | 29 Feb 2024 |
1y target est | N/A |
WAYNE, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the first quarter ended March 31, 2024. First quarter financial summary Revenues of $737.8 million, up 3.8% compared to the prior year period; up 3.8% on a constant currency basisGAAP diluted EPS from continuing operations of $0.33, compared to $1.63 in the prior year periodAdjusted diluted EPS from continuing operations of $3.21, compared to $3.09 in the prior yea
Highlights include two head-to-head randomized clinical trials (RCT) data presentations of UroLift™ System vs. other modalities to treat benign prostatic hyperplasia (BPH) -Additional studies examine post-surgery medication use, rates of hospitalization and adverse events of standard BPH treatments -Teleflex unveils latest advancements in BPH treatment with UroLift™ 2 System with Advanced Tissue Control (ATC) designed to treat all prostate types - WAYNE, Pa., May 01, 2024 (GLOBE NEWSWIRE) -- Tel
Company expands structural heart portfolio and begins the limited market release of a bipolar temporary pacing guidewire intended to introduce and position catheters and other interventional devices within the chambers of the heart while transmitting an electrical signal from an external pulse generator to the heart WAYNE, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that the Wattson™ Temporary Pacin